Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs) for mental health conditions, announced that its CEO, Michael Halstead, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference. The event, scheduled for September 14-16, 2026, in New York City, is a premier gathering for investors and industry leaders. The fireside chat will be webcast live on September 14 at 9 a.m. EDT, with a replay available on the Events & Presentations page of Helus Pharma’s investor relations website.
This announcement is significant for several reasons. First, presenting at a major investment conference provides Helus Pharma with a platform to communicate its strategic vision and clinical progress to a broad audience of institutional investors, analysts, and potential partners. The company is in a critical phase of development, with its lead candidate, HLP003, currently in Phase 3 clinical trials for the adjunctive treatment of major depressive disorder (MDD). HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA), a status that expedites the development and review of drugs intended to treat serious conditions and that have shown preliminary clinical evidence of improvement over available therapies. This designation underscores the potential of HLP003 to address a significant unmet medical need in depression treatment.
Additionally, Helus Pharma is advancing HLP004, another proprietary NSA, in Phase 2 trials for generalized anxiety disorder (GAD). The company’s focus on NSAs—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity—represents a novel approach to mental health treatment. Unlike traditional antidepressants that may take weeks to show effects, NSAs are designed to produce rapid and durable improvements by facilitating the brain’s ability to rewire itself. This mechanism has the potential to transform the treatment landscape for millions of people suffering from depression and anxiety, conditions that are among the leading causes of disability worldwide.
The participation of CEO Michael Halstead in this conference is particularly timely given the growing interest in psychedelic-inspired therapies and the need for innovative solutions in mental health care. According to the World Health Organization, depression affects more than 264 million people globally, and existing treatments are often inadequate, with many patients not achieving remission. Helus Pharma’s clinical programs aim to fill this gap by offering treatments that could provide faster and more sustained relief.
Furthermore, the company’s rebranding to Helus Pharma, with the commercial operating name derived from Cybin Inc., reflects a strategic alignment of its corporate identity with its mission to help minds heal. The company operates in Canada, the United States, the United Kingdom, and Ireland, and has an extensive research portfolio of investigational NSAs. The fireside chat at the H.C. Wainwright conference will allow investors to gain insights into the company’s development timelines, regulatory strategies, and future milestones.
For more information about the conference and to access the webcast, interested parties can visit the company’s investor relations website. The latest news and updates regarding Helus Pharma are also available in the company’s newsroom at https://ibn.fm/HELP. As Helus Pharma continues to advance its clinical programs, the outcomes of these trials could have profound implications for the future of mental health treatment, offering hope for patients who have not responded to conventional therapies.
